Advances in Translational Research and Clinical Care in Pancreatic Cancer: Where Are We Headed?

Table 2

Selected active combination immunotherapy trials.

	Pancreatic cancer classification	Clinical trial no.
Vaccine+IO
GVAX+nivolumab	Surgically resectable	NCT02451982
Vaccine+IO+radiation
GVAX+pembrolizumab+SBRT	Locally advanced	NCT02648282
GVAX+nivolumab+SBRT	Borderline resectable	NCT03161379
IO+chemotherapy
Atezolizumab+chemotherapy	Metastatic	NCT03193190
IO+radiation
Nivolumab+radiation	MSS pancreatic cancer	NCT03104439
IO+chemoradiation
Pembrolizumab+chemoradiation	Borderline resectable	NCT02305186
Nivolumab+chemo+SBRT	Locally advanced	NCT03563248

IO: immunotherapy; SBRT: stereotactic body radiation therapy; MSS: microsatellite stable.